or Try an Advanced Search...

    Technical Analysis for IMVT - Immunovant, Inc.

    Grade Last Price % Change Price Change
    F 27.49 1.18% 0.32
    IMVT closed up 1.18 percent on Monday, April 29, 2024, on 1.34 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 13
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical IMVT trend table...
    Date Alert Name Type % Chg
    Death Cross Bearish 0.00%
    NR7 Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Reached Oversold Weakness 1.18%
    Lower Bollinger Band Touch Weakness 1.18%
    Oversold Stochastic Weakness 1.18%
    Gapped Down Weakness -0.94%
    180 Bearish Setup Bearish Swing Setup -3.91%
    Lower Bollinger Band Walk Weakness -3.91%
    Oversold Stochastic Weakness -3.91%
    Older End-of-Day Signals for IMVT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 15 hours ago
    Lower Bollinger Band Support about 15 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Up 2% about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    IMVT Chart by TradingView
    Basic chart:

    Profile

    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Immune System Eye Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis

    Is IMVT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Should You Hold Immunovant (IMVT)?
    Apr 22 Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
    Apr 17 What Makes Immunovant (IMVT) a New Buy Stock
    Apr 4 Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
    Mar 25 Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
    Mar 21 Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Mar 17 11 Oversold Biotech Stocks To Buy Right Now
    Mar 14 10 Stocks George Soros and Insiders Are Crazy About
    Mar 13 Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
    Mar 12 Immunovant Awarded U.S. Patent for IMVT-1402
    See more IMVT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 45.58
    52 Week Low 17.53
    Average Volume 1,169,802
    200-Day Moving Average 32.18
    50-Day Moving Average 32.00
    20-Day Moving Average 29.57
    10-Day Moving Average 28.39
    Average True Range 1.37
    RSI (14) 33.77
    ADX 20.5
    +DI 13.22
    -DI 25.73
    Chandelier Exit (Long, 3 ATRs) 28.84
    Chandelier Exit (Short, 3 ATRs) 31.04
    Upper Bollinger Bands 32.31
    Lower Bollinger Band 26.82
    Percent B (%b) 0.12
    BandWidth 18.56
    MACD Line -1.26
    MACD Signal Line -1.15
    MACD Histogram -0.1035
    Fundamentals Value
    Market Cap 3.98 Billion
    Num Shares 145 Million
    EPS -1.96
    Price-to-Earnings (P/E) Ratio -14.03
    Price-to-Sales 0.00
    Price-to-Book 20.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 28.81
    Resistance 3 (R3) 28.77 28.29 28.59
    Resistance 2 (R2) 28.29 27.95 28.31 28.52
    Resistance 1 (R1) 27.89 27.75 28.09 27.93 28.44
    Pivot Point 27.41 27.41 27.51 27.43 27.41
    Support 1 (S1) 27.01 27.07 27.21 27.05 26.54
    Support 2 (S2) 26.53 26.87 26.55 26.46
    Support 3 (S3) 26.13 26.53 26.39
    Support 4 (S4) 26.17